华法林药物基因组学的发展及其临床应用前景  

Development of warfarin-related pharmacogenomics and its prospect of clinical application

作　　者：吴炯[1] 邬升超 郭玮[1] 潘柏申[1] 

机构地区：[1]上海复旦大学医学院附属中山医院检验科,上海200032

出　　处：《检验医学》2014年第3期209-214,共6页Laboratory Medicine

基　　金：国家临床重点检验专科建设项目;"十二五"国家科技支撑计划资助项目(2012BAI37B01)

摘　　要：华法林是临床广泛使用的口服抗凝药物。由于自身狭窄的有效抗凝治疗范围以及个体间每日用药剂量的显著差异,困扰着许多患者和临床医生。近年来,许多研究均报道基因多态性是引起华法林个体间用药剂量差异的主要因素之一。部分学者建立基于药物基因组学的剂量方程,并在进行验证,评估其临床价值。本文综述了华法林相关药物基因组学的国内外最新进展,为进一步针对华法林的临床研究提供参考依据。Warfarin,a commonly prescribed anticoagulant,has warried lots of patients and doctors because of its narrow therapeutic range and large interindividual variability in daily dose.During recent years,many studies focus on genetic polymorphisms,regarding it as one of the main effects which lead to dose difference between individuals.Some of them established and verified pharmacogenetic-based warfarin-dosing algorithms and evaluated the clinical significance.Our review exhibits the latest development of warfarin-related pharmacogenomics home and abroad,in order to provide references for further clinical studies.

关 键 词：华法林 药物基因组学 临床应用 

分 类 号：Q503[生物学—生物化学]